Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer

被引:0
|
作者
Shirbhate, Ekta [1 ]
Singh, Vaibhav [1 ]
Mishra, Aditya [1 ]
Jahoriya, Varsha [1 ]
Veerasamy, Ravichandran [2 ]
Tiwari, Amit K. [3 ]
Rajak, Harish [1 ]
机构
[1] Guru Ghasidas Univ, Dept Pharm, Bilaspur 495009, CG, India
[2] AIMST Univ, Fac Pharm, Bedong 08100, Kedah Darul Ama, Malaysia
[3] UAMS Univ Arkansas Med Sci, UAMS Coll Pharm, Little Rock, AR USA
关键词
Chemotherapeutics; exocytosis; multidrug resistance; lysosome; lysosomal sequestration; lysosomotropic agents; COPPER TRANSPORTER CTR1; CELL-DEATH; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; DRUG-RESISTANCE; LEUKEMIA-CELLS; MEMBRANE PERMEABILIZATION; ANTITUMOR-ACTIVITY; PANCREATIC-CANCER; PROGNOSTIC VALUE;
D O I
10.2174/0113895575287242240129120002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chemotherapy is still the major method of treatment for many types of cancer. Curative cancer therapy is hampered significantly by medication resistance. Acidic organelles like lysosomes serve as protagonists in cellular digestion. Lysosomes, however, are gaining popularity due to their speeding involvement in cancer progression and resistance. For instance, weak chemotherapeutic drugs of basic nature permeate through the lysosomal membrane and are retained in lysosomes in their cationic state, while extracellular release of lysosomal enzymes induces cancer, cytosolic escape of lysosomal hydrolases causes apoptosis, and so on. Drug availability at the sites of action is decreased due to lysosomal drug sequestration, which also enhances cancer resistance. This review looks at lysosomal drug sequestration mechanisms and how they affect cancer treatment resistance. Using lysosomes as subcellular targets to combat drug resistance and reverse drug sequestration is another method for overcoming drug resistance that is covered in this article. The present review has identified lysosomal drug sequestration as one of the reasons behind chemoresistance. The article delves deeper into specific aspects of lysosomal sequestration, providing nuanced insights, critical evaluations, or novel interpretations of different approaches that target lysosomes to defect cancer.
引用
收藏
页码:1449 / 1468
页数:20
相关论文
共 50 条
  • [1] Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance-A Mini Review
    Geisslinger, Franz
    Mueller, Martin
    Vollmar, Angelika M.
    Bartel, Karin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer
    Mukherjee, Soumi
    Bhatti, Gurjit Kaur
    Chhabra, Ravindresh
    Reddy, P. Hemachandra
    Bhatti, Jasvinder Singh
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 160
  • [3] The significance of targeting lysosomes in cancer immunotherapy
    Xu, Yanxin
    Shao, Bo
    Zhang, Yafeng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [4] Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
    Veiga, Rafaela Nasser
    de Azevedo, Alexandre Luiz Korte
    de Oliveira, Jaqueline Carvalho
    Gradia, Daniela Fiori
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2024, 102 (04): : 479 - 493
  • [5] Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
    Rafaela Nasser Veiga
    Alexandre Luiz Korte de Azevedo
    Jaqueline Carvalho de Oliveira
    Daniela Fiori Gradia
    Journal of Molecular Medicine, 2024, 102 : 479 - 493
  • [6] Targeting autophagy as a therapeutic strategy against pancreatic cancer
    Yamamoto, Keisuke
    Iwadate, Dosuke
    Kato, Hiroyuki
    Nakai, Yousuke
    Tateishi, Keisuke
    Fujishiro, Mitsuhiro
    JOURNAL OF GASTROENTEROLOGY, 2022, 57 (09) : 603 - 618
  • [7] Targeting autophagy as a therapeutic strategy against pancreatic cancer
    Keisuke Yamamoto
    Dosuke Iwadate
    Hiroyuki Kato
    Yousuke Nakai
    Keisuke Tateishi
    Mitsuhiro Fujishiro
    Journal of Gastroenterology, 2022, 57 : 603 - 618
  • [8] CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer
    Zhong, Chunge
    Jiang, Wen-Jie
    Yao, Yingjia
    Li, Zexu
    Li, You
    Wang, Shengnan
    Wang, Xiaofeng
    Zhu, Wenjuan
    Wu, Siqi
    Wang, Jing
    Fan, Shuangshuang
    Ma, Shixin
    Liu, Yeshu
    Zhang, Han
    Zhao, Wenchang
    Zhao, Lu
    Feng, Yi
    Li, Zihan
    Guo, Ruifang
    Yu, Li
    Pei, Fengyun
    Hu, Jun
    Feng, Xingzhi
    Yang, Zihuan
    Yang, Zhengjia
    Yang, Xueying
    Hou, Yue
    Zhang, Danni
    Xu, Dake
    Sheng, Ren
    Li, Yihao
    Liu, Lijun
    Wu, Hua-Jun
    Huang, Jun
    Fei, Teng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [9] Editorial: Targeting Lipid Rafts as a Strategy Against Infection and Cancer
    Garofalo, Tina
    Misasi, Roberta
    Preta, Giulio
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [10] Targeting SphK1 as a new strategy against cancer
    Shida, Dai
    Takabe, Kazuaki
    Kapitonov, Dmitri
    Milstien, Sheldon
    Spiegel, Sarah
    CURRENT DRUG TARGETS, 2008, 9 (08) : 662 - 673